Medincell Stock Jumps 5% at Close Boosted by Oddo BHF

Oddo BHF Reaffirms Outperformance Rating and Raises Target Price

Oddo BHF has reaffirmed its outperformance rating while raising its price target from 27 to 34 euros, indicating a potential increase of over 20% from the current price. This positive assessment comes in a favorable context for the company specialized in long-acting injectable treatments. The analysis firm expects sales of Uzedy, the antipsychotic drug developed with Teva Pharmaceuticals using BEPO technology, to be between 270 and 300 million euros in 2026. If these estimates are confirmed, Medincell could receive royalties ranging from 12 to 13 million euros. Technically, the stock is now trading above its 50-day moving average set at 27.68 euros, signaling a resurgence of bullish momentum. The RSI at 64 points confirms this positive trend without entering an overheated zone, leaving room for further progress.

Factors Justifying the Increased Target Include Anticipated Drug Approval

Among the reasons for the target increase is the expected approval of another drug in partnership with Teva: following convincing phase 3 results, the application for Olanzapine LAI was submitted on December 9 to the U.S. health authorities. Approval is hoped for in October, and Oddo BHF believes this treatment could become a blockbuster generating a billion dollars in revenue each year. Additionally, Medincell has signed a partnership with Abbvie, and the first drug from this agreement is entering the clinical phase. Over the past year, the stock has shown a remarkable performance of nearly 74%, although it has fallen back 14% over three months. The resistance threshold at 29.16 euros remains close and could be the next short-term technical target.